Endoscopic Panretinal Photocoagulation Combined With Cyclophotocoagulation In Refractory Neovascular Glaucoma
Published 2025 - 43rd Congress of the ESCRS
Reference: PO673 | Type: Free paper | DOI: 10.82333/15qv-pm45
Authors: M.Basil Marchi 1 , Adeya Al Harami* 1 , Omar Al Qahtani 1 , Joenie Anilao 1 , Ahmed Maher 2 , Javed Iqbal 3 , Hashem Abu Serhan 1
1Ophthalmology Department ,Hamad Medical Corporation,Doha,Qatar, 2Faculty of Medicine,Al-Azhar University,New-Damietta,Egypt, 3Communicable Disease Center,Hamad Medical Corporation,Doha,Qatar
Purpose
To assess the efficacy and safety of endoscopic panretinal photocoagulation (PRP) in conjunction with cyclophotocoagulation in controlling intraocular pressure (IOP) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular glaucoma (NVG) of all etiologies.
Setting
This retrospective study was conducted in a single tertiary ophthalmology center in China
Methods
This retrospective study includes 24 eyes from 24 patients. All patients underwent endoscopic PRP combined with cyclophotocoagulation. IOP and visual acuity (VA) were assessed preoperatively and postoperatively at 1 day, 1 week, 1 month, 3 months, 6 months and 12 months. Anterior chamber reactions and complications were also observed. Statistical analysis was performed to evaluate the significance of the outcomes.
Results
The postoperative IOP was reduced from 50.17±8.18mmHg to 16.83±3.25 mmHg at 1-day, 17.5±5.72 at 7-day, 27.33±16.15mmHg at 1-months, 19.00±5.70 mmHg at 3-months, 21.40±6.59 mmHg at 6-months and 20.20±5.17 mmHg at 12-months. Postoperative glaucoma medication burden was reduced from baseline (3.33±0.52) to 12-month (0.29±0.90). No medication success rate was 75.00% and qualified success rate was 100.00% at 12-months. Visual acuity remained stable before and after the procedure.
Conclusions
Combining endoscopic PRP and ECP surgery in refractory NVG patients after anti-VEGF injections effectively controls IOP without serious complications for 12 months. Larger sample sizes and longer follow-up periods are needed to assess its long-term safety and efficacy.